Alembic

Alembic Pharmaceuticals has received final USFDA approval for its abbreviated new drug application (ANDA) travoprost ophthalmic solution USP, 0.004%. The approved ANDA is therapeutically equivalent […]

Alembic Pharmaceuticals through its joint venture firm Aleor Dermaceuticals has received USFDA approval for Desonide Ointment. The Desonide Ointment with a strength of 0.05 per […]

Alembic Pharmaceuticals through its joint venture (JV) firm Aleor Dermaceuticals has received final USFDA approval for Clobetasol Propionate spray, used to treat plaque psoriasis. The […]

Alembic Pharmaceuticals has received USFDA approval for Pregabalin Capsules, indicated for management of neuropathic pain associated with certain illnesses. The drug is a therapeutically equivalent […]

Alembic Pharmaceuticals has received USFDA approval for Clonazepam orally disintegrating tablets which are used for treatment of seizures, adjunct in the treatment of the Lennox-Gastaut […]

Alembic Pharmaceuticals has received USFDA approval from for Bromfenac Ophthalmic Solution, used for treatment of post-operative inflammation and reduction of ocular pain in patients who […]

Alembic Pharmaceuticals has received final USFDA approval for Oseltamivir Phosphate capsules, used for treatment of influenza infection. The drug is therapeutically equivalent to the reference […]

Alembic Pharmaceuticals has received USFDA approval for Solifenacin Succinate tablets which are used for treatment of over-active bladder. The product Solifenacin Succinate is a generic […]

Alembic Pharmaceuticals has received USFDA approval for Carbidopa and Levodopa extended-release tablets which is used for treatment of Parkinson’s disease. The drug is therapeutically equivalent […]

Alembic Pharmaceuticals has received final USFDA approval for Tadalafil tablets, indicated for the treatment of erectile dysfunction. The drug will be marketed in strengths of […]